February 1974

Early Splenectomy in Lymphoproliferative Disorders

Author Affiliations


From the Blood Research laboratory, New England Medical Center Hospitals and the Department of Medicine, Tufts University School of Medicine, Boston. Both authors are presently at the Scripps Clinic and Research Foundation, La Jolla, Calif.

Arch Intern Med. 1974;133(2):270-274. doi:10.1001/archinte.1974.00320140108011

Early splenectomy for hypersplenism was performed on 50 patients with chronic lymphocytic leukemia (CLL), lymphosarcoma leukemic reticuloendotheliosis (LRE), reticulum cell sarcoma (RCS), and Hodgkin disease. Postoperative complications were infrequent. However, the effect of splenectomy on survival cannot be determined because no control study was done. Patients with CLL, LRE, and well-differentiated lymphosarcoma generally did better than those with RCS, poorly differentiated lymphosarcoma, and Hodgkin disease. Early splenectomy is recommended in CLL, LRE, and well-differentiated lymphosarcoma once hypersplenism has developed. It also is indicated in Hodgkin disease and hypersplenism but it should be recommended with caution in RCS and poorly differentiated lymphosarcoma.